{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"This is a count of patients who did not have a clot (thromboembolism) occur during the 4 weeks of study - attributed to the use of Fondaparinux (study dry). Prophylaxis is a measure taken for the prevention of a disease or condition.","groups":[{"description":"This number includes all patients that completed 4 weeks of the study and were treated with 2.5 mg of Fondaparinux on days 1-28.","id":"OG000","title":"Fondaparinux Patients Who Completed Study"}],"paramType":"NUMBER","populationDescription":"These patients completed the study and are considered evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 4","title":"Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.","type":"SECONDARY","unitOfMeasure":"Participants"}